Molbio Diagnostics IPO: ₹281.5 Crore Raised Ahead of ₹940 Crore Issue

Molbio Diagnostics, the Goa-based molecular diagnostics company, has raised ₹281.5 crore ahead of its proposed ₹940 crore initial public offering (IPO), strengthening its financial position as it prepares to enter the public markets. The company, known for its point-of-care molecular diagnostic platform, is scheduled to open its IPO for public subscription from August 10 to August 12, 2026.

Molbio Diagnostics IPO Price Band and Issue Structure

The IPO has been fixed in the price band of ₹768–₹807 per equity share. The issue comprises a fresh issue of ₹200 crore and an offer for sale (OFS) of approximately ₹739.7 crore, taking the total issue size to around ₹939.7 crore. The fresh capital is expected to support Molbio’s growth and expansion plans, while the OFS component will provide an exit opportunity to existing shareholders. View full IPO details on our Investor Relations page

About Molbio Diagnostics and the Truenat Platform

Molbio Diagnostics develops and manufactures point-of-care molecular diagnostic systems, with its flagship Truenat platform enabling molecular testing closer to the point of patient care. The company’s diagnostics portfolio is designed to support the detection of infectious diseases and other conditions in decentralised healthcare settings, particularly where conventional laboratory infrastructure may be limited.  Explore the Truenat Platform

Molbio Diagnostics’ Financial Growth: FY24 to FY26

The company has reported strong financial growth in recent years. Molbio’s revenue increased from approximately ₹840.6 crore in FY24 to ₹1,028 crore in FY25, while profit after tax rose from around ₹83.5 crore to ₹138.6 crore during the same period. FY26 revenue stood at approximately ₹1,455 crore, with profit after tax at around ₹164 crore, according to reported financial data.

Why the Molbio Diagnostics IPO Matters for India’s Diagnostics Sector

Molbio’s IPO comes amid increasing investor interest in India’s diagnostics and healthcare technology sector, driven by growing demand for rapid, decentralised and technology-enabled testing. The company’s focus on point-of-care molecular diagnostics positions it within a market increasingly seeking faster diagnosis and improved access to advanced testing outside conventional laboratories.

What’s Next After the Molbio Diagnostics IPO

Molbio’s upcoming public issue is expected to provide the company with additional capital and visibility as it expands its diagnostic technology footprint in India and international markets. The IPO will also mark an important milestone for India’s indigenous molecular diagnostics industry as domestic MedTech companies increasingly look to scale through public-market funding.  About Molbio Diagnostics